Singapore, March 6 -- Australia's Monash University has announced the award of support from the Advanced Research Projects Agency for Health (ARPA-H) to advance an oral prodrug of celecoxib - using the GlyphTM platform, designed to deliver therapy directly to the gut lymphatics - aiming to improve lymphatic function and advance the treatment of metabolic disease and pancreatic cancer by directly addressing local inflammation and lymphatic dysfunction.

The project is being led by the Monash Institute of Pharmaceutical Sciences (MIPS) in partnership with long term collaborator, Seaport Therapeutics, and is being backed by up to AUD$21.5 million via the ARPA-H GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) programme.

T...